The Filing Desk

Celularity vs NewAmsterdam Pharma

Celularity CELU · NewAmsterdam Pharma NAMS · Pharmaceuticals

Celularity reported revenue of $26 million in fiscal 2025, 1.2 times NewAmsterdam Pharma's $22 million in fiscal 2025. Celularity's revenue fell 51.0% in its latest year, and NewAmsterdam Pharma's fell 50.6%. Celularity had an operating margin of -230.9%, against -1002.9% at NewAmsterdam Pharma.

Side by side

CelularityNewAmsterdam Pharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$26M$22M
Revenue growth−51.0%−50.6%
Revenue growth a year, last 5 years13.1%—
Gross margin24.4%—
Operating margin−230.9%−1,002.9%
Net margin−345.4%−905.7%
Free cash flow—−$148M
Free cash flow margin—−657.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count16.9%25.5%
Last close$0.47$19.51
P/E at the last close——
Insider trades, last 12 months—bought $226,500, sold $62.0 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CelularityNewAmsterdam Pharma
Operating margin
Percent of revenue
CelularityNewAmsterdam Pharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CelularityNewAmsterdam Pharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celularity and NewAmsterdam Pharma pages.